Acrivon Therapeutics Inc. Common Stock

ACRV | NASDAQ

Price Alert Chart Builder DCF Calculator

$2.01

+$0.16 (+8.65%)

At close: Sep 21, 2026, 4:00 PM ET

$1.88

-$0.13 (-6.71%)

Pre-market: Sep 22, 2026, 8:49 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+8.65%

(1D)

Rating

Updated: Aug 24, 2026

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $86.03M

1D Range

1.89 2.03

52W Range

1.27 3.56

Valuation (TTM)

PE -1.07

PB 0.99

EV/EBITDA 0.02

Valuation (NTM)

Forward PE N/A

Forward PEG 0.17

Price Target $21.83

Cash Flow

FCF Yield -74.5%

SBC Adj. FCF Yield -87.8%

SBC Impact -17.8%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y N/A | N/A

Dil EPS 3Y | 5Y 19.4% | -11.5%

FCF 3Y | 5Y -6.9% | -30.9%

Returns

ROA -74.9%

ROE -70.1%

ROIC -88.3%

Financial Health

Net Cash

$87.84M

Current Ratio 7.99

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumor...

Sector Healthcare

Industry Biotechnology

Employees 75

IPO Date Nov 14, 2022

Website www.acrivon.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 12, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$20

Upside

+895.02%

Buy (2)

Hold (0)

Sell (0)

Analyst Details ➞